A #FIDELITY Analysis on #Finerenone With #SGLT2i and #GLP1RA in CKD

#VisualAbstract by Cristina Popa

www.kireports.org/article/S2468-0249(25)00...

Finerenone Shows Benefits in Hereditary ATTR Finerenone is effective for kidney protection in hereditary ATTR even in patients with heart failure and preserved ejection fraction.

#Finerenone is effective in kidney protection in patients with hereditary transthyretin amyloidosis (#ATTR), even in patients with #HeartFailure and preserved ejection fraction. Study in @ndt-era.bsky.social

Read here: https://bit.ly/4qSWtUW

#RareDisease #HereditaryTransthyretinAmyloidosis

Promising Outcomes of FINE-ONE Trial for Type 1 Diabetes Patients with Chronic Kidney Disease Recent findings from the FINE-ONE trial reveal that finerenone shows promise in treating chronic kidney disease linked to type 1 diabetes, making strides in patient care.

Promising Outcomes of FINE-ONE Trial for Type 1 Diabetes Patients with Chronic Kidney Disease #USA #Houston #Breakthrough_T1D #FINE-ONE_Trial #Finerenone

Now that FINE-ONE has shown that #finerenone ⬇️ proteinuria in #ckd w type 1 diabetes #t1d, it'll be difficult for insuranfe companies to deny. But what about the egfr trajectories shown today at #kidneywk?
Reflective of false stabilization of egfr on placebo or something else?

Now that FINE-ONE has shown that #finerenone ⬇️ proteinuria in #ckd w type 1 diabetes #t1d, it'll be difficult for insuranfe companies to deny. But what about the egfr trajectories shown today at #kidneywk?
Reflective of false stabilization of egfr on placebo or something else?

FINE-ONE was just presented at @asnkidney.bsky.social at #KidneyWk. #Finerenone significantly reduced #UACR by 25% at 6 months in patients with #T1D & #CKD - an understudied population with high unmet need.

💊Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: The Fine-Heart Pooled Analysis
✅Significantly lower deaths of any cause, CV events and kidney outcomes but failed to demonstrated significant reductions in CV death
#NephJC
#finerenone
@theisn.org @nephjc.bsky.social

Truth and Pitfalls of Evidence-Based Medicine
By Dr. Vito Campese @keck.usc.edu

Full text 👉 buff.ly/BRX3eiN

#OpenAccess
#RASi
#Finerenone
#SGLT2
#Nephrology
#KidneyCare
#KidneyHealth
#nephsky
#medsky
#RenalPath

Combination Therapy for Chronic Kidney Disease and Type 2 Diabetes — A Promising Prelude | NEJM The rising tide of chronic kidney disease among patients with type 2 diabetes continues to challenge clinicians and health systems worldwide.1 Advances have been made in the management of chronic k...

News for #CKD and ##T2D treatment

#finerenone #empagliflozin
#nephjc

www.nejm.org/doi/full/10....

Efficacy and Tolerability of Finerenone According to the Use and Dosage of Diuretics This secondary analysis of the FINEARTS-HF randomized clinical trial examines the efficacy and tolerability of finerenone related to background diuretic treatment in patients with heart failure with m...

Finerenona reduce el uso de diuréticos en pacientes con insuficiencia cardíaca con fracción de eyección levemente reducida o preservada, aunque no reduce el inicio de los diuréticos del asa #finerenone #diuretics #HF jamanetwork.com/journals/jam...

🌟🌟ICYMI🌟🌟
🔎Check out articles in the July KI

doi.org/10.1016/j.kint.2025.04.012

🔹 Benefits of #finerenone not affected by acute GFR changes
🔹 Autosomal dominant polycystic kidney disease in children
🔹 A natural product fights #tubulointerstitialfibrosis
⭐And More!
#NephSky #MedSky #ADPKD #pedsneph

Finerenone–empagliflozin combination outperforms monotherapy in CKD with type 2 diabetes In patients with chronic kidney disease and type 2 diabetes, finerenone plus empagliflozin combination therapy outperforms either monotherapy for UACR reduction.

#MedNews - In patients with #CKD and type 2 diabetes, #finerenone plus #empagliflozin combination therapy outperforms either monotherapy for UACR reduction.

Full story 👉 buff.ly/B7bvKuT

#Diabetes #T2D

Combo Therapy That Slashes UACR Could Be a Game Changer for CKD | Docwire News Rajiv Agarwal, MBBS, discussed a study showing that a finerenone and empagliflozin combination has superior efficacy at reducing UACR in chronic kidney disease and type 2 diabetes.

✔️ Check out our interview with Rajiv Agarwal, who presented at #ERA25 on the efficacy of pairing #finerenone and #empagliflozin to lower UACR. #nephsky #nephrology #kidneydisease #ckd #diabetes www.docwirenews.com/post/combo-t...

How will the #CONFIDENCE trial shape practice in #CKD + #T2D?

I spoke with PI, Rajiv Agarwal, after his #ERA25 late-breaker on why a sequential approach may be doing our patients a disservice

Full episode: hcplive.com/view/kidney-...

#KidneyCompass #SGLT2i #finerenone

Dual therapy with finerenone + empagliflozin cut albuminuria by ~30% more than either drug alone in CKD + T2D—with no added safety concerns.
A promising step for combo treatment in DKD.
#CKD #T2D #SGLT2i #Finerenone #CONFIDENCE #Nephrology #BlueskyMD

https://www.nejm.org/doi/full/10.1056/NEJMoa2410659

In the CONFIDENCE trial, combo therapy with #finerenone + #empagliflozin led to a >50% reduction in albuminuria over 180 days in patients with #CKD & #T2D — significantly greater than either drug alone. Safe, effective, synergistic.
👉 www.nejm.org/doi/full/10....

🦸‍♂️🦸‍♀️ Meet the Dynamic Duo in HFpEF/HFrEF!

SGLT2 inhibitors🟰Robin
Finerenone🟰Batman

Together they battle heart failure💔 with preserved/mid-range EF!

🔗 doi.org/10.36660/abc...

#NephSky #CardioRenal #HFpEF #SGLT2i #Finerenone #HeartFailure #MedSky #InternalMedicine

Podocyte Talk Episode 24:
– SGLT2i vs GLP-1RA in real-world CKD care
– Finerenone works regardless of early eGFR drop
– High-carb diets raise mortality in dialysis patients

#Nephrology #KidneyCare #Finerenone #SGLT2i #GLP1RA
#podocytetalk #Nephpearls #Nephrology #CKD

youtu.be/uMbtbhPYBPc

Interim US Results From the FINE-REAL Study | Docwire News At SCM25, researchers presented results of an interim analysis of the FINE-REAL study of finerenone among patients with chronic kidney disease (CKD) and type 2 diabetes.

An interim analysis of FINE-REAL data described characteristics, concomitant therapy, dosing, treatment patterns, and safety of #finerenone. #nephrology #nephsky #kidney #type2diabetes #kidneydisease #CKD #NKFClinicals www.docwirenews.com/post/interim...

Analysis of the prespecified FIDELITY pooled patient dataset examined the efficacy and safety of #finerenone in patients with an acute change in #estimatedglomerularfiltrationrate

doi.org/10.1016/j.kint.2025.03.018

#OpenAccess #MedSky #NephSky #kidney #eGFR

Finerenone Reduces New-Onset Atrial Fibrillation across the Spectrum of Cardio-Kidney-Metabolism: the FINE-HEART Pooled Analysis:

Finerenona reduce el riesgo de fibrilación o flúter auricular de diagnóstico reciente a través del espectro cardio-renal-metabólico #finerenone #AF www.jacc.org/doi/10.1016/...

【日本人CKD合併２型DM例eGFRに対するフィネレノンの影響は？/ KI Rep】

日本、単施設管理下でフィネレノン開始後１年以上継続のCKD合併２型DM 106例解析：

・82.1%がRASi、88.7%がSGLT2-iを服用。
・フィネレノン開始後、eGFR低下は2.29 mL/分/1.73m2/年の有意抑
　制。
・RAS-i併用例では遅延作用減弱傾向？

x.gd/58vdp
#Finerenone #eGFR

Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial Finerenone and glycaemic status in patients with heart failure with mildly reduced/preserved ejection fraction. CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; RR, r...

#Finerenone reduced the risk of CV death and total worsening HF events, and was well-tolerated, independent of glycaemic status in HFmrEF/HFpEF

@escardio.bsky.social @shelleyzieroth.bsky.social @drrajivsankar.bsky.social @docbhardwaj.bsky.social

onlinelibrary.wiley.com/doi/full/10....

#Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the #FINEARTS-HF trial

onlinelibrary.wiley.com/doi/full/10.... @escardio.bsky.social #CardioSky @

Sign up for reminders so you Never Miss a Beat bit.ly/4eqyaac

#atrialfibrillation #CVD #Finerenone #ESCTVToday

#Finerenone and new-onset #diabetes in #heartfailure: a prespecified analysis of the FINEARTS-HF trial www.thelancet.com/journals/lan... #T2D
#OpenAccess
#MedSky #EndoSky #CardioSky

#Finerenone: CV & renal protection across all #T2D therapies❗️

🔹 Pooled analysis: 15,365 pts w/ T2D + CKD or CV

🔸 Consistent benefit on 💔☠️, 🏥💔& kidney outcomes

🔹 ⤴️K+ ⤵️ with SGLT2i use

🔸 Benefit independent of SGLT2i/GLP-1 use

👉 Supports finerenone as a 🎯 in high-risk #T2D❗️

🔗 ggdocs.co/tx2a5r

Finerenone and Outpatient Worsening Heart Failure With Mildly Reduced or Preserved Ejection Fraction This secondary analysis of the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF) randomized clinical trial evaluates the effect of fi...

Finerenona reduce los eventos de empeoramiento ambulatorio de la insuficiencia cardíaca que requieren intensificación de diuréticos orales, que se asocian con un peor pronóstico en pacientes con fracción de eyección levemente reducida o preservada #finerenone #HFpEF jamanetwork.com/journals/jam...

Could finerenone reduce new-onset diabetes in patients with Heart Failure?

Carlos Aguiar discusses novel data from the FINEARTS-HF trial and much more on Cardiology This Week #ESCTVToday bit.ly/3WU6UKk

Sign up for reminders so you Never Miss a Beat bit.ly/4hoqoiB

#finerenone #heartfailure

Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial.

www.thelancet.com/journals/lan...

@thelancet.bsky.social

#CardioSky #MedSky #Finerenone #Cardiology
#FINEARTS-HF #HeartFailure #Diabetes